Abbvie Inc ABBV:NYSE

Last Price$163.94NYSE Closing Price as of 4:10PM ET 12/05/22
NYSE 15-minute delayed Bid/Ask Quotes
Today's Change+0.28(0.17%)
Bid (Size)$163.82 (1)
Ask (Size)$164.58 (1)
Day Low / High$162.89 - 165.19
Volume4.9 M
  • Latest Stories
  • Commentary and Analysis
AbbVie Says European Commission Approves Skyrizi for Treatment of Crohn's Disease
3:42AM ET 11/23/2022 MT Newswires

AbbVie (ABBV) said Wednesday the European Commission approved its Skyrizi drug for the treatment of adult patients with moderate to severe Crohn's disease,...

Market Chatter: Teva Pharmaceutical Industries, Sandoz Plan to Boost Production of Biosimilars
9:10AM ET 11/22/2022 MT Newswires

Teva Pharmaceutical Industries (TEVA) and Sandoz plan to boost the production of biosimilars to raise their share in that market, Reuters reported Tuesday,...

AbbVie Says Epcoritamab Obtains FDA Priority Review for Treatment of Large B-Cell Lymphoma
8:44AM ET 11/21/2022 MT Newswires

AbbVie (ABBV) said Monday the US Food and Drug Administration has accepted for priority review the company's biologics license application for epcoritamab,...

Credit Suisse Starts AbbVie at Outperform With $170 Price Target
8:08AM ET 11/18/2022 MT Newswires

AbbVie (ABBV) has an average rating of outperform and price targets ranging from $120 to $200, according to analysts polled by Capital IQ. (MT Newswires...

AbbVie Gets Health Canada Approval for Ubrelvy Tablet to Treat Migraines
12:14PM ET 11/16/2022 MT Newswires

AbbVie (ABBV) said Wednesday Health Canada has approved its Ubrelvy tablet for the acute treatment of migraine, with or without aura, in adults. Ubrelvy...

--Societe Generale Downgrades AbbVie to Hold From Buy
12:04PM ET 11/08/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

AbbVie Says Phase 2 Trial of Neurotoxin for Prevention of Complication in Cardiac Surgery Patients Fails to Meet Primary Endpoint
2:33PM ET 11/07/2022 MT Newswires

AbbVie (ABBV) said Monday that the phase 2 study of AGN-151607, an investigational neurotoxin for the prevention of postoperative atrial fibrillation, a...

--UBS Lifts AbbVie's Price Target to $147 From $146, Keeps Neutral Rating
12:17PM ET 10/31/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Research Alert: CFRA Cuts View On Shares Of Abbvie Inc. To Hold From Buy
11:50AM ET 10/31/2022 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

Research Alert: CFRA Cuts View On Shares Of Abbvie Inc. To Hold From Buy
11:45AM ET 10/31/2022 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...